Soricimed Biopharma Inc. Strengthens Executive Team with Appointment of Dr. Michael Groaning PhD, as Chief Scientific Officer
New Brunswick and Boston, Massachusetts--(Newsfile Corp. - September 2, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on developing precision oncology drugs, today announced the appointment of Dr. Michael Groaning PhD, as Chief Scientific Officer (CSO). This strategic addition underscores Soricimed's commitment to advancing its TRPV6-targeting Radioligand Therapies (RLT) pipeline and driving long-term value for patients and stakeholders....
2025-09-02 7:30 AM EDT
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
New Brunswick, Canada--(Newsfile Corp. - January 13, 2025) - Soricimed Biopharma Inc. ("Soricimed"), a clinical-stage biopharmaceutical company focused on developing Peptide Drug Conjugates, is pleased to announce the appointment of Dr. Neil Fleshner as an Executive Member of the Board of Directors. Dr. Fleshner brings decades of clinical, academic, and research leadership in oncology, with a distinguished career centered on cancer prevention, treatment innovation, and translational research....
2025-01-13 8:25 AM EST